浅析我国药品数量多和《基本药物目录》品种数量少的问题  

Analysis on the Situation of Abundant Drugs vs. Few Categories Involved in Essential Drug List in China

作　　者：孟锐[1] 杨奔[1] 丁丽曼[1] 

机构地区：[1]黑龙江中医药大学,哈尔滨市150040

出　　处：《中国药房》2010年第20期1850-1851,共2页China Pharmacy

摘　　要：目的:为促进我国《国家基本药物目录》的调整,加快推行基本药物制度提供参考。方法:比较我国2004年版《国家基本药物目录》与世界卫生组织《基本药物目录》,查阅国家食品药品监督管理局的统计结果,结合我国实际情况,分析我国药品数量多、《国家基本药物目录》品种数量少的问题。结果与结论:由于我国原料药市场庞大,药品剂型丰富,对药品生产企业的监管不力,导致了生产企业盲目增加剂型,增加品种数量的现状;基本药物价廉、质优、"基本"、国家承担的特点决定了《基本药物目录》品种数量不宜过多。我国《国家基本药物目录》应随着实践不断调整,以满足人民健康所需。OBJECTIVE：To promote the adjustment of National Essential Drug List and implementation of Essential Drug List. METHODS：National Essential Drug List was compared with Essential Drug List issued by WHO. Retrieved from statistical results conducted by State Food and Drug Administration, the problem that there were large number of drug in China while little category were included in National Essential Drug List was analyzed, according to practice in China. RESULTS CONCLUSION： Drug enterprises increased the dosage form and category of preparation blindly because of huge raw drug market, various dosage forms and weak administration to drug enterprises. The characteristics of drug were cheap, high quality, acceptance by state, which decided that the category of drug in Essential Drug List should not be too much. It is necessary to adjust Essential Drug List as the change of situation so as to meet the requirement of public health.

关 键 词：药品 基本药物 基本药物目录 品种 数量 

分 类 号：R95[医药卫生—药学]